Galderma is celebrating the 25th anniversary of Restylane, a non-animal stabilized hyaluronic acid filler that works to restore, enhance, and refresh skin. Restylane launched in Europe in 1996, and was first approved by the U.S. Food and Drug Administration (FDA) in 2003. The Restylane portfolio continues to grow and expand, as Restylane Eyelight launched earlier in September 2021 and in February 2021, the FDA approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. “The depth of experience from Restylane over the last 25 years has enabled us to build upon our expertise to innovate and develop new formulations and treatments," says Flemming Ørnskov, M.D., MPH CEO of Galderma. "With more than 30 ongoing pipeline projects in aesthetics alone, we will continue to enhance our diverse and broad portfolio of sophisticated brands to advance dermatology for every skin story.”
Related Articles
Galderma Partners With Sofregen
Report Examines Hyaluronic Acid Filler Hypersensitivity After COVID-19
Galderma Receives FDA Approval for Cheek Fillers